Martin Schmidt

This inventor holds 16 USPTO granted patents and 11 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignees: Abbvie Deutschland Gmbh and Co Kg, Abbvie Inc., Basf Aktiengesellschaft. Active years: 2000-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin Schmidt. Retrieved from https://idiyas.com/inventor/martin-schmidt-t3gwxipi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 11)

% Patents Active = 50.0

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 7.8

ph-index = 4

Forward Citations = 76(Granted Patents)

Location History:

Duisburg, DE (2012)
Benshelm, DE (2016)
Bensheim, DE (2000 - 2018)
Ludwigshafen, DE (2017 - 2020)

Company Filing History:

9 out of 167

Abbvie Deutschland Gmbh and Co Kg

Basf Aktiengesellschaft

Abbott Laboratories Corporation

patents

6. 1 out of 186

Foseco International Limited

patents

where one patent can have more than one assignee

Years Active: 2000-2020

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10556914 - Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use (2020-02-11),

2. 10155770 - Substituted pyrazolopyrimidines and method of use (2018-12-18),

3. 10040852 - Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof (2018-08-07),

4. 9828381 - Substituted pyrazolopyrimidines and method of use (2017-11-28),

5. 9605069 - Antibodies against the RGM a protein and uses thereof (2017-03-28),

6. 9394363 - Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof (2016-07-19),

7. 9291621 - AGER-peptides and use thereof (2016-03-22),

8. 9255146 - Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof (2016-02-09),

9. 8962803 - Antibodies against the RGM A protein and uses thereof (2015-02-24),

10. 8323651 - Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof (2012-12-04),

11. 8158053 - Refractory articles (2012-04-17),

12. 7906120 - Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) (2011-03-15),

13. 7491729 - 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof (2009-02-17),

14. 6683055 - Low molecular weight inhibitors of complement proteases (2004-01-27),

15. 6066502 - Endothelin converting enzyme (ECE) (2000-05-23),

Title: Innovations of Martin Schmidt

Introduction

Martin Schmidt, an accomplished inventor based in Bensheim, Germany, holds an impressive portfolio of 15 patents. His work primarily revolves around advancements in pharmaceutical compounds that target specific therapeutic areas.

Latest Patents

Schmidt's latest innovations include two significant patents: the first involves substituted isoxazolopyridazinones and isothiazolopyridazinones, which are described as compounds of formula (I) and their pharmaceutically acceptable salts. These compounds are reported to be useful in treating conditions or disorders that can be prevented or ameliorated by positive allosteric modulation of the gamma-aminobutyric acid B (GABA-B) receptor. The patent also details methods for creating these compounds and outlines pharmaceutical compositions and their applications.

The second innovative patent pertains to substituted pyrazolopyrimidines, again represented as compounds of formula (I) and their pharmaceutically acceptable salts. Similar to the first patent, these compounds are intended for treating conditions affected by the modulation of the GABA-B receptor. The methodologies for their synthesis and potential pharmaceutical use are also thoroughly described in this patent.

Career Highlights

Throughout his career, Martin Schmidt has collaborated with prominent companies in the pharmaceutical sector, including AbbVie Deutschland GmbH & Co. KG and AbbVie Inc. His contributions to these organizations have facilitated significant advancements in therapeutic drug development.

Collaborations

Schmidt has worked alongside notable colleagues such as Achim Moeller and Reinhold Mueller. Their teamwork has likely played a vital role in the research leading to the successful validation and patenting of new pharmaceutical compounds.

Conclusion

In summary, Martin Schmidt's innovative contributions to the field of pharmaceuticals, marked by his numerous patents, demonstrate his commitment to advancing medical science. His work plays a crucial role in the development of new therapies that can significantly improve patients' lives.

Profile summary based on public USPTO records.